| Literature DB >> 33960629 |
Anping Cai1, Dan Zhou1, Lin Liu1, Yingling Zhou1, Songtao Tang2, Yingqing Feng1.
Abstract
The study was to compare age-related alterations in cardiac and arterial structure and function by sex and to explore the impacts of achieved systolic blood pressure (SBP; <130 mm Hg vs. <140 mm Hg) level on age-related alterations in cardiac and arterial structure and function in hypertensive women and men. Community hypertensive individuals without cardiovascular disease who had echocardiographic examination were included. Age-related alterations in cardiac and arterial structure and function were compared by sex, and interplay between age and sex was analyzed according to achieved SBP level. The mean age of the cohort was 66.5 years, and women accounted for 62% (n = 602) of the cohort (n = 971). Compared to men, women had worse left ventricular (LV) diastolic function and greater LV and arterial stiffness. After adjusting for covariates, the magnitude of the associations between age with septal E/e' ratio, septal S' velocity, effective arterial elastance (Ea) and LV end-diastolic elastance (Eed) were greater in women. Sex differences in the magnitude of association between age with these four indices varied according to achieved SBP level. When achieved SBP <130 mm Hg, the magnitude of the associations between age with septal E/e' ratio, septal S' velocity, Ea and Eed did not differ by sex. Since age and sex are non-modifiable, achieving SBP target, especially at a lower level, might be beneficial to attenuate sex differences in age-related alterations in cardiac and arterial structure and function.Entities:
Keywords: age; arterial function; cardiac structure and function; sex; systolic blood pressure
Mesh:
Year: 2021 PMID: 33960629 PMCID: PMC8678835 DOI: 10.1111/jch.14262
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738
Baseline characteristics
| Variables | Overall ( | Men ( | Women ( |
|
|---|---|---|---|---|
| Age (years) | 66.5 ± 11.4 | 64.2 ± 12.3 | 67.8 ± 10.7 | <.001 |
| SBP (mm Hg) | 137.0 ± 16.7 | 136.9 ± 15.8 | 137.1 ± 17.2 | .893 |
| DBP (mm Hg) | 81.9 ± 10.5 | 83.8 ± 10.7 | 80.8 ± 10.2 | <.001 |
| Heart rate (beat per minute) | 71.7 ± 12.0 | 72.0 ± 12.3 | 71.5 ± 11.8 | .572 |
| Smoking, | 208 (21.4) | 203 (55.0) | 5 (0.8) | <.001 |
| Physical inactivity, | 408 (42.0) | 148 (40.1) | 260 (43.2) | .38 |
| Body surface area (m2) | 1.62 ± 0.18 | 1.73 ± 0.15 | 1.55 ± 0.15 | <.001 |
| Body mass index (kg/m2) | 25.3 ± 3.8 | 24.9 ± 3.5 | 25.5 ± 3.9 | .024 |
| Obesity, | 205 (21.1) | 61 (16.5) | 144 (23.9) | .008 |
| Waist/hip ratio | 0.93 ± 0.06 | 0.94 ± 0.05 | 0.92 ± 0.06 | <.001 |
| Dyslipidemia, | 597 (75.6) | 209 (71.1) | 388 (78.2) | .03 |
| Diabetes mellitus, | 216 (22.3) | 75 (20.3) | 141 (23.5) | .283 |
| Hyperuricemia, | 614 (64.7) | 244 (67.4) | 370 (63.0) | .194 |
| CKD, | 124 (13.3) | 50 (14.0) | 74 (12.8) | .684 |
| FPG (mmol/L) | 5.4 ± 1.5 | 5.3 ± 1.6 | 5.4 ± 1.5 | .379 |
| Total cholesterol (mg/dl) | 211.1 ± 53.5 | 200.1 ± 49.6 | 217.9 ± 54.7 | <.001 |
| LDL cholesterol (mg/dl) | 129.1 ± 38.4 | 125.3 ± 37.2 | 131.6 ± 39.0 | .072 |
| HDL cholesterol (mg/dl) | 53.5 ± 14.4 | 50.2 ± 16.1 | 55.7 ± 12.7 | <.001 |
| Triglyceride (mg/dl) | 132.6 [96.2, 190.7] | 128.5 [93.6, 190.1] | 135.0 [97.5, 193.2] | .994 |
| Creatinine (µmol/L) | 79.3 ± 35.1 | 94.7 ± 46.0 | 69.7 ± 21.2 | <.001 |
| eGFR (ml/min/1.73 m2) | 83.5 ± 24.0 | 82.4 ± 23.8 | 84.2 ± 24.1 | .27 |
| Uric acid (µmol/L) | 429.2 ± 124.2 | 471.4 ± 121.9 | 403.2 ± 118.3 | <.001 |
| Aspirin, | 167 (17.2) | 73 (19.8) | 94 (15.6) | .113 |
| Statins, | 272 (28.0) | 112 (30.4) | 160 (26.6) | .231 |
| Oral antidiabetics, | 175 (18.0) | 64 (17.3) | 111 (18.4) | .73 |
| Insulin, | 4 (0.4) | 3 (0.8) | 1 (0.2) | .312 |
| Allopurinol, | 22 (2.3) | 12 (3.3) | 10 (1.7) | .163 |
| ACEI, | 144 (14.8) | 62 (16.8) | 82 (13.6) | .207 |
| ARB, | 489 (50.4) | 187 (50.7) | 302 (50.2) | .929 |
| CCB, | 454 (46.8) | 166 (45.0) | 288 (47.8) | .424 |
| Diuretic, | 137 (14.1) | 63 (17.1) | 74 (12.3) | .047 |
| Betablocker, | 127 (13.1) | 48 (13.0) | 79 (13.1) | 1 |
| No. antihypertensive drugs | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | .302 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure.
Presented as median [Q1, Q3].
FIGURE 1Age distributions in women and men. Panel A: overall participants; Panel B men; Panel C women
Cardiac and arterial structure and function
| Variables | Overall ( | Men ( | Women ( |
|
|---|---|---|---|---|
| Left atrial volume (ml) | 42.8 ± 21.0 | 42.7 ± 22.5 | 42.9 ± 20.0 | .885 |
| Left atrial volume index (ml/m2) | 26.5 ± 13.2 | 24.7 ± 13.4 | 27.6 ± 13.0 | .001 |
| Left atrial volume index >34 ml/m2, | 180 (18.5) | 50 (13.6) | 130 (21.6) | .004 |
| Interventricular septum thickness (mm) | 9.7 ± 1.3 | 10.0 ± 1.3 | 9.5 ± 1.3 | <.001 |
| Posterior wall thickness (mm) | 9.5 ± 1.8 | 9.8 ± 1.9 | 9.3 ± 1.8 | <.001 |
| Relative wall thickness | 0.43 ± 0.09 | 0.43 ± 0.09 | 0.43 ± 0.08 | .245 |
| Relative wall thickness >0.42, | 493 (50.8) | 197 (53.4) | 296 (49.2) | .226 |
| LVEDD (mm) | 44.7 ± 4.4 | 45.8 ± 4.6 | 44.1 ± 4.1 | <.001 |
| LVESD (mm) | 27.5 ± 4.2 | 28.6 ± 4.5 | 26.9 ± 3.8 | <.001 |
| LVEDV (ml) | 92.4 ± 22.0 | 97.9 ± 24.0 | 89.1 ± 19.9 | <.001 |
| LVEDV index (ml/m2) | 57.1 ± 12.6 | 56.5 ± 13.0 | 57.5 ± 12.3 | .246 |
| LVESV (ml) | 29.4 ± 12.4 | 32.4 ± 14.5 | 27.6 ± 10.4 | <.001 |
| LVESV index (ml/m2) | 18.1 ± 7.3 | 18.7 ± 8.1 | 17.8 ± 6.8 | .067 |
| Left ventricular mass (g) | 146.2 ± 42.1 | 159.0 ± 45.5 | 138.4 ± 37.9 | <.001 |
| Left ventricular mass index (g/m2) | 90.1 ± 23.8 | 91.7 ± 25.0 | 89.1 ± 23.0 | .105 |
| Left ventricular hypertrophy, | 242 (24.9) | 53 (14.4) | 189 (31.4) | <.001 |
| LVMV ratio (g/ml) | 1.59 ± 0.32 | 1.64 ± 0.33 | 1.57 ± 0.32 | .001 |
| Left ventricular geometry | ||||
| Normal, | 375 (38.6) | 150 (40.7) | 225 (37.4) | .342 |
| Concentric remodeling, | 354 (36.5) | 166 (45.0) | 188 (31.2) | <.001 |
| Concentric hypertrophy, | 103 (10.6) | 22 (6.0) | 81 (13.5) | <.001 |
| Eccentric hypertrophy, | 139 (14.3) | 31 (8.4) | 108 (17.9) | <.001 |
| Septal S′ velocity (cm/s) | 6.4 ± 1.5 | 6.8 ± 1.4 | 6.2 ± 1.6 | <.001 |
| Left ventricular ejection fraction (%) | 67.6 ± 7.1 | 66.7 ± 7.0 | 68.2 ± 7.0 | .001 |
| Stroke volume (ml) | 65.0 ± 14.9 | 68.0 ± 15.9 | 63.1 ± 13.9 | <.001 |
| Stroke volume index (ml/m2) | 40.3 ± 8.5 | 39.4 ± 8.4 | 41.0 ± 8.5 | .041 |
| Peak E‐wave velocity (m/s) | 0.68 ± 0.21 | 0.67 ± 0.21 | 0.69 ± 0.21 | .05 |
| Peak A‐wave velocity (m/s) | 0.87 ± 0.19 | 0.82 ± 0.20 | 0.90 ± 0.18 | <.001 |
| E/A ratio | 0.80 ± 0.25 | 0.85 ± 0.30 | 0.77 ± 0.22 | <.001 |
| Septal e′ velocity (cm/s) | 5.5 ± 1.8 | 5.9 ± 1.8 | 5.2 ± 1.7 | <.001 |
| Septal e′ velocity <7 cm/s, | 728 (75.0) | 239 (64.8) | 489 (81.2) | <.001 |
| Septal E/e′ ratio | 13.4 ± 5.4 | 12.0 ± 5.3 | 14.3 ± 5.2 | <.001 |
| Septal E/e′ ratio >15, | 273 (28.1) | 57 (15.4) | 216 (35.9) | <.001 |
| Ees (mm Hg/ml) | 4.74 ± 1.80 | 4.35 ± 1.88 | 4.98 ± 1.71 | <.001 |
| Eed (mm Hg/ml) | 0.23 ± 0.06 | 0.21 ± 0.06 | 0.24 ± 0.06 | <.001 |
| Ea (mm Hg/ml) | 1.99 ± 0.52 | 1.93 ± 0.52 | 2.03 ± 0.52 | .03 |
| Ea/Ees ratio | 0.47 ± 0.17 | 0.50 ± 0.19 | 0.45 ± 0.15 | <.001 |
| Pulse pressure (mm Hg) | 55.2 ± 14.4 | 53.2 ± 14.0 | 56.4 ± 14.5 | .001 |
Abbreviations: Ea, effective arterial elastance; Eed, left ventricular end‐diastolic elastance; Ees, left ventricular end‐systolic elastance; LVEDD, left ventricular end‐diastolic diameter; LVEDV, left ventricular end‐diastolic volume; LVESD, left ventricular end‐systolic diameter; LVESV, left ventricular end‐systolic volume; LVMV, left ventricular mass‐to‐volume.
FIGURE 2Alterations in cardiac and arterial structure and function across increasing age groups in women and men. Across increasing age groups, there was a trend of increase in LA volume index (Panel A), septal E/e′ ratio (Panel C) and pulse pressure (Panel G) and a trend of decrease in septal e′ velocity (Panel B) and septal S′ velocity (Panel M) in women and men. There was a trend of increase in Ees (Panel E), Eed (Panel D), Ea (Panel F), and LVM index (Panel I) with increasing age only in women, and no significant trend of alterations in Ea/Ees (Panel H), LVMV ratio (Panel J), LVEF (Panel K), and SV index (Panel L) with increasing age in both sexes. Blue line indicates men and red line indicates women. Ea, effective arterial elastance; Eed, left ventricular end‐diastolic elastance; Ees, left ventricular end‐systolic elastance; LA, left atrial; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMV, left ventricular mass‐to‐volume; SV, stroke volume
Association between age with indices of cardiac and arterial structure and function
| Per 10 years increase in age | β‐coefficient (95% confidence interval) | ||
|---|---|---|---|
| Men | Women |
| |
| Left atrial volume index (ml/m2) | 1.53 (−0.34, 3.40) | 0.97 (−0.55, 2.48) | .637 |
| Septal e′ velocity (cm/s) | −0.55 (−0.68, −0.41) | −0.74 (−0.85, −0.63) | .029 |
| Septal E/e′ ratio | 0.36 (−0.08, 0.80) | 1.39 (1.01, 1.77) | <.001 |
| Left ventricular mass index (g/m2) | 1.64 (−0.44, 3.71) | 2.04 (0.31, 3.76) | .768 |
| LVMV ratio (g/ml) | 0.004 (−0.020, 0.028) | 0.004 (−0.024, 0.031) | .988 |
| LVEF (%) | 0.06 (−0.53, 0.64) | −0.31 (−0.84, 0.22) | .36 |
| SV index (ml/m2) | 0.60 (−0.37, 1.57) | −0.01 (−0.91, 0.89) | .364 |
| Septal S′ (m/s) | −0.30 (−0.42, −0.19) | −0.47 (−0.58, −0.36) | .038 |
| Ees (mm Hg/ml) | 0.06 (−0.10, 0.21) | 0.24 (0.11, 0.36) | .071 |
| Eed (mm Hg/ml) | 0.006 (0.001, 0.010) | 0.016 (0.01, 0.020) | .004 |
| Ea (mm Hg/ml) | 0.04 (−0.02, 0.10) | 0.13 (0.07, 0.18) | .038 |
| Ea/Ees ratio | 0.010 (−0.012, 0.032) | 0.001 (−0.014, 0.017) | .501 |
| Pulse pressure (mm Hg) | 3.10 (1.98, 4.23) | 3.91 (2.87, 4.95) | .303 |
Adjusting for smoking, body mass index, waist/hip ratio, diabetes mellitus, eGFR, uric acid and antihypertensive drugs.
Abbreviations: Ea, effective arterial elastance; Eed, left ventricular end‐diastolic elastance; Ees, left ventricular end‐systolic elastance; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMV, left ventricular mass‐to‐volume; SV, stroke volume.
Impacts of the achieved SBP level on age‐related changes in selected indices of cardiac and arterial structure and function
| Per 10 years increase in age | Adjusted β‐coefficient (95% confidence interval) | ||
|---|---|---|---|
|
|
|
|
|
| Septal S′ (m/s) | −0.58 (−0.82, −0.34) | −0.39 (−0.60, −0.18) | .569 |
| Septal E/e′ ratio | 1.01 (0.39, 1.62) | 1.27 (0.40, 2.15) | .325 |
| Ea (mm Hg/ml) | −0.02 (−0.13, 0.08) | 0.12 (0.06, 0.18) | .488 |
| Eed (mm Hg/ml) | 0.006 (−0.003, 0.015) | 0.011 (0.001, 0.021) | .286 |
|
|
|
|
|
| Septal S′ (m/s) | −0.13 (−0.31, 0.05) | −0.45 (−0.62, −0.29) | .014 |
| Septal E/e′ ratio | 0.48 (−0.23, 1.18) | 1.42 (0.89, 1.94) | .003 |
| Ea (mm Hg/ml) | 0.05 (−0.04, 0.14) | 0.14 (0.07, 0.22) | .019 |
| Eed (mm Hg/ml) | 0.005 (−0.003, 0.012) | 0.016 (0.009, 0.022) | .002 |
|
|
|
|
|
| Septal S′ (m/s) | −0.30 (−0.48, −0.12) | −0.50 (−0.69, −0.32) | .197 |
| Septal E/e′ ratio | 0.38 (−0.36, 1.12) | 1.26 (0.67, 1.85) | .026 |
| Ea (mm Hg/ml) | 0.01 (−0.06, 0.09) | 0.06 (−0.01, 0.13) | .184 |
| Eed (mm Hg/ml) | 0.004 (−0.004, 0.012) | 0.011 (0.004, 0.018) | .067 |
|
|
|
|
|
| Septal S′ (m/s) | −0.21 (−0.45, 0.04) | −0.36 (−0.54, −0.17) | .082 |
| Septal E/e′ ratio | 1.22 (0.59, 1.85) | 1.65 (0.96, 2.34) | .049 |
| Ea (mm Hg/ml) | 0.08 (−0.06, 0.21) | 0.16 (0.06, 0.26) | .034 |
| Eed (mm Hg/ml) | 0.011 (0.003, 0.019) | 0.018 (0.009, 0.026) | .016 |
Adjusting for smoking, body mass index, waist/hip ratio, diabetes mellitus, eGFR, uric acid and antihypertensive drugs.
Abbreviations: Ea, effective arterial elastance; Eed, left ventricular end‐diastolic elastance; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.